GE HealthCare Technologies (NASDAQ:GEHC) Raised to Buy at The Goldman Sachs Group

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) was upgraded by research analysts at The Goldman Sachs Group from a "neutral" rating to a "buy" rating in a report released on Tuesday, Marketbeat Ratings reports. The firm currently has a $100.00 price target on the stock, up from their previous price target of $85.00. The Goldman Sachs Group's target price suggests a potential upside of 17.15% from the company's previous close.

Several other research analysts also recently weighed in on GEHC. Citigroup boosted their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Wells Fargo & Company increased their target price on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. Finally, Jefferies Financial Group raised GE HealthCare Technologies from a "hold" rating to a "buy" rating and upped their target price for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $98.75.

GE HealthCare Technologies Stock Performance

NASDAQ:GEHC opened at $85.36 on Tuesday. The business's fifty day moving average price is $86.91 and its 200 day moving average price is $86.17. GE HealthCare Technologies has a 12 month low of $74.51 and a 12 month high of $94.80. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. The firm has a market capitalization of $39.03 billion, a PE ratio of 19.71, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13.

Remove Ads

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The firm had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.33 billion. On average, sell-side analysts anticipate that GE HealthCare Technologies will post 4.68 earnings per share for the current fiscal year.

Institutional Trading of GE HealthCare Technologies

Several institutional investors have recently bought and sold shares of GEHC. CoreFirst Bank & Trust bought a new position in GE HealthCare Technologies in the 4th quarter worth approximately $25,000. Ashton Thomas Securities LLC bought a new position in shares of GE HealthCare Technologies during the 3rd quarter valued at about $26,000. Capital Performance Advisors LLP bought a new position in GE HealthCare Technologies in the third quarter valued at approximately $26,000. Runnymede Capital Advisors Inc. acquired a new position in GE HealthCare Technologies in the 4th quarter worth $28,000. Finally, LGT Financial Advisors LLC grew its holdings in shares of GE HealthCare Technologies by 46.2% during the fourth quarter. LGT Financial Advisors LLC now owns 389 shares of the company's stock worth $30,000 after buying an additional 123 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.